Viral Genetics acquires facility in California

13 December 2001

Viral Genetics of the USA has entered into a $1.8 million agreement topurchase a property in South Pasadena, California, which will be used as its first commercial-scale production facility. The company is developing therapeutic products based on the biologically-active linear protein, Thymus Nuclear Protein.

The company has completed clinical trials of TNP on HIV-infected and fulminate AIDS multi-drug-cocktail-resistant patients in Mexico, and expects to apply for registration of the product there before the end of 2001. Haig Keledjian, Viral Genetics' president, said the new facility allows the firm to meet the expected demand for TNP from the combination of Mexican government purchases and sale of the drug to private clinics in that country, starting next year.

He added that it is also "a concrete and explicit demonstration of our confidence in the Mexican project, as well as our ongoing endeavors elsewhere.''

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.